
Opinion|Videos|December 3, 2024
The Impact of Biomarkers and Modern Disease-Modifying Therapies in MS
Author(s)Gabriel Pardo, MD, FAAN, Martin Belkin, DO
Panelists discuss how modern multiple sclerosis (MS) management has evolved from symptomatic treatment to a proactive, personalized approach leveraging advanced biomarkers and sophisticated disease-modifying therapies. The focus has shifted toward early intervention, precise monitoring, and comprehensive disease control, significantly improving patient outcomes and quality of life.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please share how your management of MS has changed in recent years with the availability of biomarkers and highly efficacious disease-modifying therapies.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Efgartigimod Shows Non-Inferior Disability Improvement and Greater Muscle Strength Recovery Versus Plasma Exchange in Real-World GBS Study
2
The Promise and Limitations of Neurofilament Light Chain in Peripheral Nerve Disorders: Brett Morrison, MD, PhD
3
IVIg and Plasma Exchange Show Comparable Functional Outcomes in Guillain-Barre Syndrome
4
Neurofilament Light Chain Levels Track Disease Activity and Decline With Efgartigimod Treatment in CIDP
5















